Goldman Sachs’s Amryt Pharma AMYT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
– Sell
-163,968
Closed -$2.39M – 6292
2023
Q1
$2.39M Buy
+163,968
New +$2.32M ﹤0.01% 3724
2022
Q4
– Sell
-10,609
Closed -$73K – 6411
2022
Q3
$73K Sell
10,609
-684
-6% -$5.1K ﹤0.01% 5753
2022
Q2
$79K Sell
11,293
-533
-5% -$4.16K ﹤0.01% 5931
2022
Q1
$98K Sell
11,826
-3,284
-22% -$29.6K ﹤0.01% 6116
2021
Q4
$163K Sell
15,110
-11,911
-44% -$129K ﹤0.01% 5977
2021
Q3
$326K Buy
+27,021
New +$305K ﹤0.01% 5450

Goldman Sachs's AMYT Position: Q2 2023 in Review

Goldman Sachs sold out of Amryt Pharma (AMYT) in Q2 2023, closing a stake of 163,968 shares — an estimated $2.39M sold.

Goldman Sachs first reported a position in AMYT in Q3 2021 and held it in 6 quarters. The position peaked at $2.39M in Q1 2023. 0 funds tracked by Wall St. Rank hold AMYT as of Q2 2023.

  • Goldman Sachs reported no remaining Amryt Pharma position as of Q2 2023 after selling out during the quarter.
  • Goldman Sachs sold 163,968 Amryt Pharma shares in Q2 2023, an estimated $2.39M.
  • Goldman Sachs first reported a position in Amryt Pharma in Q3 2021 and held it in 6 quarters.
  • Goldman Sachs's Amryt Pharma position peaked at $2.39M in Q1 2023.
  • 0 funds tracked by Wall St. Rank held Amryt Pharma as of Q2 2023.

Based on Goldman Sachs's 13F filing for Q2 2023, filed 15 Aug 2023.